{"pmid":32298134,"title":"Antiplatelet Therapy Following Percutaneous Coronary Intervention in Patients Complicated by COVID-19: Implications from Clinical Features to Pathological Findings.","text":["Antiplatelet Therapy Following Percutaneous Coronary Intervention in Patients Complicated by COVID-19: Implications from Clinical Features to Pathological Findings.","Circulation","Zhou, Xin","Li, Yongle","Yang, Qing","32298134"],"journal":"Circulation","authors":["Zhou, Xin","Li, Yongle","Yang, Qing"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298134","week":"202016|Apr 13 - Apr 19","doi":"10.1161/CIRCULATIONAHA.120.046988","keywords":["COVID-19"],"source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1664266651281915905,"score":8.233237,"similar":[{"pmid":32299781,"title":"Precautions and Procedures for Coronary and Structural Cardiac Interventions During the COVID-19 Pandemic: Guidance from Canadian Association of Interventional Cardiology.","text":["Precautions and Procedures for Coronary and Structural Cardiac Interventions During the COVID-19 Pandemic: Guidance from Canadian Association of Interventional Cardiology.","The globe is currently in the midst of a COVID-19 pandemic, resulting in significant morbidity and mortality. This pandemic has placed considerable stress on health care resources and providers. This document from the Canadian Association of Interventional Cardiology- Association Canadienne de Cardiologie d'intervention, specifically addresses the implications for the care of patients in the cardiac catheterization laboratory (CCL) in Canada during the COVID-19 pandemic. The key principles of this document are to maintain essential interventional cardiovascular care while minimizing risks of COVID-19 to patients and staff and maintaining the overall health care resources. As the COVID-19 pandemic evolves, procedures will be increased or reduced based on the current level of restriction to health care services. Although some consistency across the country is desirable, provincial and regional considerations will influence how these recommendations are implemented. We believe the framework and recommendations in this document will provide crucial guidance for clinicians and policy makers on the management of coronary and structural procedures in the CCL as the COVID-19 pandemic escalates and eventually abates.","Can J Cardiol","Wood, David A","Sathananthan, Janarthanan","Gin, Ken","Mansour, Samer","Ly, Hung Q","Quraishi, Ata-Ur-Rehman","Lavoie, Andrea","Lutchmedial, Sohrab","Nosair, Mohamed","Bagai, Akshay","Bainey, Kevin R","Boone, Robert H","Liu, Shuangbo","Krahn, Andrew","Virani, Sean","Mehta, Shamir R","Natarajan, Madhu K","Velianou, James L","Dehghani, Payam","Wijeysundera, Harindra C","Asgar, Anita W","Virani, Alice","Welsh, Robert C","Webb, John G","Cohen, Eric A","32299781"],"abstract":["The globe is currently in the midst of a COVID-19 pandemic, resulting in significant morbidity and mortality. This pandemic has placed considerable stress on health care resources and providers. This document from the Canadian Association of Interventional Cardiology- Association Canadienne de Cardiologie d'intervention, specifically addresses the implications for the care of patients in the cardiac catheterization laboratory (CCL) in Canada during the COVID-19 pandemic. The key principles of this document are to maintain essential interventional cardiovascular care while minimizing risks of COVID-19 to patients and staff and maintaining the overall health care resources. As the COVID-19 pandemic evolves, procedures will be increased or reduced based on the current level of restriction to health care services. Although some consistency across the country is desirable, provincial and regional considerations will influence how these recommendations are implemented. We believe the framework and recommendations in this document will provide crucial guidance for clinicians and policy makers on the management of coronary and structural procedures in the CCL as the COVID-19 pandemic escalates and eventually abates."],"journal":"Can J Cardiol","authors":["Wood, David A","Sathananthan, Janarthanan","Gin, Ken","Mansour, Samer","Ly, Hung Q","Quraishi, Ata-Ur-Rehman","Lavoie, Andrea","Lutchmedial, Sohrab","Nosair, Mohamed","Bagai, Akshay","Bainey, Kevin R","Boone, Robert H","Liu, Shuangbo","Krahn, Andrew","Virani, Sean","Mehta, Shamir R","Natarajan, Madhu K","Velianou, James L","Dehghani, Payam","Wijeysundera, Harindra C","Asgar, Anita W","Virani, Alice","Welsh, Robert C","Webb, John G","Cohen, Eric A"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32299781","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.cjca.2020.03.027","source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"locations":["Canada"],"countries":["Canada"],"countries_codes":["CAN|Canada"],"_version_":1664357978667483136,"score":72.66891},{"pmid":32282949,"title":"Hematological findings and complications of COVID-19.","text":["Hematological findings and complications of COVID-19.","COVID-19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the disease course, longitudinal evaluation of lymphocyte count dynamics and inflammatory indices, including LDH, CRP and IL-6 may help to identify cases with dismal prognosis and prompt intervention in order to improve outcomes. Biomarkers, such high serum procalcitonin and ferritin have also emerged as poor prognostic factors. Furthermore, blood hypercoagulability is common among hospitalized COVID-19 patients. Elevated D-Dimer levels are consistently reported, whereas their gradual increase during disease course is particularly associated with disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin degradation products increase, with severe thrombocytopenia lead to life-threatening Disseminated intravascular coagulation (DIC) which necessitates continuous vigilance and prompt intervention. COVID-19 infected patients whatever hospitalized or ambulatory are at high risk for VTE and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended. Last but not least, the need for assuring blood donations during the pandemic is also highlighted.","Am J Hematol","Terpos, Evangelos","Ntanasis-Stathopoulos, Ioannis","Elalamy, Ismail","Kastritis, Efstathios","Sergentanis, Theodoros N","Politou, Marianna","Psaltopoulou, Theodora","Gerotziafas, Grigoris","Dimopoulos, Meletios A","32282949"],"abstract":["COVID-19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the disease course, longitudinal evaluation of lymphocyte count dynamics and inflammatory indices, including LDH, CRP and IL-6 may help to identify cases with dismal prognosis and prompt intervention in order to improve outcomes. Biomarkers, such high serum procalcitonin and ferritin have also emerged as poor prognostic factors. Furthermore, blood hypercoagulability is common among hospitalized COVID-19 patients. Elevated D-Dimer levels are consistently reported, whereas their gradual increase during disease course is particularly associated with disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin degradation products increase, with severe thrombocytopenia lead to life-threatening Disseminated intravascular coagulation (DIC) which necessitates continuous vigilance and prompt intervention. COVID-19 infected patients whatever hospitalized or ambulatory are at high risk for VTE and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended. Last but not least, the need for assuring blood donations during the pandemic is also highlighted."],"journal":"Am J Hematol","authors":["Terpos, Evangelos","Ntanasis-Stathopoulos, Ioannis","Elalamy, Ismail","Kastritis, Efstathios","Sergentanis, Theodoros N","Politou, Marianna","Psaltopoulou, Theodora","Gerotziafas, Grigoris","Dimopoulos, Meletios A"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282949","week":"202016|Apr 13 - Apr 19","doi":"10.1002/ajh.25829","source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Lymphopenia"],"e_drugs":["Heparin, Low-Molecular-Weight"],"_version_":1664182200856215552,"score":70.99352},{"pmid":32270559,"title":"Cardiac and arrhythmic complications in Covid-19 patients.","text":["Cardiac and arrhythmic complications in Covid-19 patients.","In December 2019, the world started to face a new pandemic situation, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although COVID-19 clinical manifestations are mainly respiratory, major cardiac complications are being reported. Cardiac manifestations etiology seems to be multifactorial, comprising direct viral myocardial damage, hypoxia, hypotension, enhanced inflammatory status, ACE2-receptors downregulation, drug toxicity, endogenous catecholamine adrenergic status, among others. Studies evaluating COVID-19 patients presenting cardiac injury markers show that it is associated with poorer outcomes, and arrhythmic events are not uncommon. Besides, drugs currently used to treat the COVID-19 are known to prolong the QT interval and can have a proarrhythmic propensity. This review focus on COVID-19 cardiac and arrhythmic manifestations and, in parallel, makes an appraisal of other virus epidemics as SARS-CoV, MERS-CoV, and H1N1 influenza. This article is protected by copyright. All rights reserved.","J Cardiovasc Electrophysiol","Kochi, Adriano Nunes","Tagliari, Ana Paula","Forleo, Giovanni Battista","Fassini, Gaetano Michele","Tondo, Claudio","32270559"],"abstract":["In December 2019, the world started to face a new pandemic situation, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although COVID-19 clinical manifestations are mainly respiratory, major cardiac complications are being reported. Cardiac manifestations etiology seems to be multifactorial, comprising direct viral myocardial damage, hypoxia, hypotension, enhanced inflammatory status, ACE2-receptors downregulation, drug toxicity, endogenous catecholamine adrenergic status, among others. Studies evaluating COVID-19 patients presenting cardiac injury markers show that it is associated with poorer outcomes, and arrhythmic events are not uncommon. Besides, drugs currently used to treat the COVID-19 are known to prolong the QT interval and can have a proarrhythmic propensity. This review focus on COVID-19 cardiac and arrhythmic manifestations and, in parallel, makes an appraisal of other virus epidemics as SARS-CoV, MERS-CoV, and H1N1 influenza. This article is protected by copyright. All rights reserved."],"journal":"J Cardiovasc Electrophysiol","authors":["Kochi, Adriano Nunes","Tagliari, Ana Paula","Forleo, Giovanni Battista","Fassini, Gaetano Michele","Tondo, Claudio"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32270559","week":"202015|Apr 06 - Apr 12","doi":"10.1111/jce.14479","keywords":["Arrhythmia","COVID-19","Myocardial damage","Myocarditis","SARS-CoV-2"],"source":"PubMed","locations":["hypoxia"],"topics":["Treatment","Diagnosis"],"weight":1,"e_drugs":["Catecholamines"],"_version_":1663620083035930624,"score":64.75112},{"pmid":32198776,"title":"Clinical features and treatment of COVID-19 patients in northeast Chongqing.","text":["Clinical features and treatment of COVID-19 patients in northeast Chongqing.","The outbreak of the novel coronavirus in China (SARS-CoV-2) that began in December 2019 presents a significant and urgent threat to global health. This study was conducted to provide the international community with a deeper understanding of this new infectious disease. Epidemiological, clinical features, laboratory findings, radiological characteristics, treatment, and clinical outcomes of 135 patients in northeast Chongqing were collected and analyzed in this study. A total of 135 hospitalized patients with COVID-19 were enrolled. The median age was 47 years (interquartile range, 36-55), and there was no significant gender difference (53.3% men). The majority of patients had contact with people from the Wuhan area. Forty-three (31.9%) patients had underlying disease, primarily hypertension (13 [9.6%]), diabetes (12 [8.9%]), cardiovascular disease (7 [5.2%]), and malignancy (4 [3.0%]). Common symptoms included fever (120 [88.9%]), cough (102 [76.5%]), and fatigue (44 [32.5%]). Chest computed tomography scans showed bilateral patchy shadows or ground glass opacity in the lungs of all the patients. All patients received antiviral therapy (135 [100%]) (Kaletra and interferon were both used), antibacterial therapy (59 [43.7%]), and corticosteroids (36 [26.7%]). In addition, many patients received traditional Chinese medicine (TCM) (124 [91.8%]). It is suggested that patients should receive Kaletra early and should be treated by a combination of Western and Chinese medicines. Compared to the mild cases, the severe ones had lower lymphocyte counts and higher plasma levels of Pt, APTT, d-dimer, lactate dehydrogenase, PCT, ALB, C-reactive protein, and aspartate aminotransferase. This study demonstrates the clinic features and therapies of 135 COVID-19 patients. Kaletra and TCM played an important role in the treatment of the viral pneumonia. Further studies are required to explore the role of Kaletra and TCM in the treatment of COVID-19.","J Med Virol","Wan, Suxin","Xiang, Yi","Fang, Wei","Zheng, Yu","Li, Boqun","Hu, Yanjun","Lang, Chunhui","Huang, Daoqiu","Sun, Qiuyan","Xiong, Yan","Huang, Xia","Lv, Jinglong","Luo, Yaling","Shen, Li","Yang, Haoran","Huang, Gu","Yang, Ruishan","32198776"],"abstract":["The outbreak of the novel coronavirus in China (SARS-CoV-2) that began in December 2019 presents a significant and urgent threat to global health. This study was conducted to provide the international community with a deeper understanding of this new infectious disease. Epidemiological, clinical features, laboratory findings, radiological characteristics, treatment, and clinical outcomes of 135 patients in northeast Chongqing were collected and analyzed in this study. A total of 135 hospitalized patients with COVID-19 were enrolled. The median age was 47 years (interquartile range, 36-55), and there was no significant gender difference (53.3% men). The majority of patients had contact with people from the Wuhan area. Forty-three (31.9%) patients had underlying disease, primarily hypertension (13 [9.6%]), diabetes (12 [8.9%]), cardiovascular disease (7 [5.2%]), and malignancy (4 [3.0%]). Common symptoms included fever (120 [88.9%]), cough (102 [76.5%]), and fatigue (44 [32.5%]). Chest computed tomography scans showed bilateral patchy shadows or ground glass opacity in the lungs of all the patients. All patients received antiviral therapy (135 [100%]) (Kaletra and interferon were both used), antibacterial therapy (59 [43.7%]), and corticosteroids (36 [26.7%]). In addition, many patients received traditional Chinese medicine (TCM) (124 [91.8%]). It is suggested that patients should receive Kaletra early and should be treated by a combination of Western and Chinese medicines. Compared to the mild cases, the severe ones had lower lymphocyte counts and higher plasma levels of Pt, APTT, d-dimer, lactate dehydrogenase, PCT, ALB, C-reactive protein, and aspartate aminotransferase. This study demonstrates the clinic features and therapies of 135 COVID-19 patients. Kaletra and TCM played an important role in the treatment of the viral pneumonia. Further studies are required to explore the role of Kaletra and TCM in the treatment of COVID-19."],"journal":"J Med Virol","authors":["Wan, Suxin","Xiang, Yi","Fang, Wei","Zheng, Yu","Li, Boqun","Hu, Yanjun","Lang, Chunhui","Huang, Daoqiu","Sun, Qiuyan","Xiong, Yan","Huang, Xia","Lv, Jinglong","Luo, Yaling","Shen, Li","Yang, Haoran","Huang, Gu","Yang, Ruishan"],"date":"2020-03-22T11:00:00Z","year":2020,"_id":"32198776","week":"202012|Mar 16 - Mar 22","doi":"10.1002/jmv.25783","keywords":["COVID-19","clinical features","cognition","northeast Chongqing","treatment"],"source":"PubMed","locations":["Western","Chinese","Wuhan","China","Chongqing"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1663352133577080832,"score":62.67716},{"pmid":32285027,"pmcid":"PMC7138353","title":"Breast Cancer Diagnosis, Treatment and Follow-Up During COVID-19 Pandemic.","text":["Breast Cancer Diagnosis, Treatment and Follow-Up During COVID-19 Pandemic.","Eur J Breast Health","Soran, Atilla","Gimbel, Michael","Diego, Emilia","32285027"],"journal":"Eur J Breast Health","authors":["Soran, Atilla","Gimbel, Michael","Diego, Emilia"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32285027","week":"202016|Apr 13 - Apr 19","doi":"10.5152/ejbh.2020.240320","source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1664071627180081152,"score":61.691936}]}